Pilot study of intravenous glyburide in patients with a large ischemic stroke

Stroke

Volumn 45, Issue 1, 2014, Pages 281-283

  Sheth, Kevin N ^a   Kimberly, W Taylor ^b   Elm, Jordan J ^d   Kent, Thomas A ^e   Mandava, Pitchaiah ^e   Yoo, Albert J ^c   Thomalla, Götz ^f   Campbell, Bruce ^g   Donnan, Geoffrey A ^g   Davis, Stephen M ^g   Albers, Gregory W ^h   Jacobson, Sven ⁱ   Simard, J Marc ^j   Stern, Barney J ^k  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Neurocritical Care and Emergency Neurology   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Remedy Pharmaceuticals Inc   (United States)

^j SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Acute treatment; Brain swelling; Cerebral edema; Glyburide; Hemorrhagic transformation; Ischemic stroke

Indexed keywords

EID: 84893689596     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/Strokeaha.113.003352     Document Type: Article

References (9)

1. Simard JM, Chen M, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L, et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med. 2006;12:433-440.
2. Simard JM, Woo SK, Gerzanich V. Transient receptor potential melastatin 4 and cell death. Pflugers Arch. 2012;464:573-582.
3. Simard JM, Yurovsky V, Tsymbalyuk N, Melnichenko L, Ivanova S, Gerzanich V. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke. 2009;40:604-609.
4. Simard JM, Tsymbalyuk N, Tsymbalyuk O, Ivanova S, Yurovsky V, Gerzanich V. Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke. 2010;41:531-537.
5. Thomalla G, Hartmann F, Juettler E, Singer OC, Lehnhardt FG, Köhrmann M, et al; Clinical Trial Net of the German Competence Network Stroke. Prediction of malignant middle cerebral artery infarction by magnetic resonance imaging within 6 hours of symptom onset: a prospective multicenter observational study. Ann Neurol. 2010;68:435-445.
6. Johnston KC, Hall CE, Kissela BM, Bleck TP, Conaway MR; GRASP Investigators. Glucose Regulation in Acute Stroke Patients (GRASP) trial: a randomized pilot trial. Stroke. 2009;40:3804-3809.
7. Yoo AJ, Sheth KN, Kimberly WT, Chaudhry ZA, Elm JJ, Jacobson S, et al. Validating imaging biomarkers of cerebral edema in patients with severe ischemic stroke. J Stroke Cerebrovasc Dis. 2013;22: 742-749.
8. Kunte H, Busch MA, Trostdorf K, Vollnberg B, Harms L, Mehta RI, et al. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann Neurol. 2012;72:799-806.
9. Vahedi K, Hofmeijer J, Juettler E, Vicaut E, George B, Algra A, et al; DECIMAL, DESTINY, and HAMLET Investigators. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6:215-222.